The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda

AIDS

Volumn 20, Issue 6, 2006, Pages 907-914

  Marseille, Elliot ^a   Saba, Joseph ^b   Muyingo, Sowedi ^c   Kahn, James G ^d  

^a Health Strategies International   (United States)

^b Axios International   (France)

^c Axios Internacional   (Uganda)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Africa; AIDS; Antiretroviral therapy; Cost benefit analysis; HIV; Private sector; Trimethoprim sulfamethoxazole combination therapeutic use

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE COURSE; EMPLOYEE; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PRODUCTIVITY; PROPHYLAXIS; UGANDA;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG COSTS; EMPLOYER HEALTH COSTS; HIV INFECTIONS; HUMANS; MODELS, ECONOMETRIC; OCCUPATIONAL HEALTH SERVICES; PRIVATE SECTOR; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; UGANDA;

EID: 33646694570     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000218556.36661.47     Document Type: Article

References (40)

1. The Policy Project, USAID. How does HIV/AIDS affect African businesses? Washington, DC: USAID; 2000.
2. Kambou G, Devarajan S, Over M. The economic impact of AIDS in an African country: simulations with a computable general equilibrium model of Cameroon. J Afric Econ 1992; 1:109-130.
3. Forsythe S, Rau B. AIDS in Kenya: Socio-economic impact and policy implications. Arlington, VA: AIDSCAP/FHI; 1996.
4. Bollinger L, Stover J. The economic impact of AIDS in South Africa. Washington DC: The Futures Group International; 1999.
5. UNAIDS. Putting HIV/AIDS on the business agenda. Geneva: UNAIDS; 1998.
6. Fox MP, Rosen S, MacLeod WB, Wasunna M, Bii M, Foglia G, et al. The impact of HIV/AIDS on labour productivity in Kenya. Trop Med Int Health 2004; 9:318-324.
7. UNAIDS. 2004 report on the global HIV/AIDS epidemic: 4th global report. Geneva: UNAIDS; 2004.
8. De Beers. De Beers Group HIV/AIDS business case-study. Southsdale, South Africa: De Beers; 2005.
9. World Economic Forum. Global health initiative, private sector intervention case example: DaimlerChrysler. Geneva: World Economic Forum; 2003.
10. Anglo American Group. Anti-retroviral therapy programme - progress report. Available at: www.angloamerican.co.uk. 2004.
11. PricewaterhouseCoopers. HIV/AIDS: What is business doing? A survey of the business community's response to HIV/AIDS in Kenya, Tanzania, Uganda and Zambia. Pricewaterhouse-Coopers; 2003.
12. World Bank. World development report 1993: investing in health. New York: Oxford University Press; 1993.
13. UNAIDS, WHO. Provisional WHO/UNAIDS Secretariat recommendations on the use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa. Geneva: UNAIDS, WHO; 2000.
14. Anglaret X, Chene G, Attia A, Toure S, Lafont S, Combe P, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Cotrimo-CI Study Group [see comments]. Lancet 1999; 353:1463-1468.
15. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364:1428-1434.
16. Kahn JG, Haile B, Kates J, Chang S. Health and federal budgetary effects of increasing access to antiretroviral medications for HIV by expanding Medicaid. Am J Public Health 2001; 91:1464-1473.
17. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730.
18. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341:1865-1873.
19. Saag MS, Tebas P, Sension M, Conant M, Myers R, Chapman SK, et al. Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511). AIDS 2001; 15:1971-1978.
20. Cathe J Jr, Badaro R, Grimwood A, Abrams L, Klesczewski K, Cross A, et al. Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir. J Acquir Immune Defic Syndr 2002; 31:399-403.
21. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
22. UNAIDS/WHO. Antibiotic recommended for African HIV patients. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) Meeting in Geneva. Geneva: UNAIDS/WHO; 2000.
23. World Health Organization. Interim proposal for a WHO staging system for HIV infection and disease. Wkly Epidemiol Rec 1990; 65:221-224.
24. Morgan D, Malamba SS, Maude GH, Okongo MJ, Wagner HU, Mulder DW, et al. An HIV-1 natural history cohort and survival times in rural Uganda. AIDS 1997; 11:633-640.
25. Jawe E. Recurring goods: Quantities and unit costs. In. Home-based care program, Tororo District. Entebbe: Medical Stores, Centers for Disease Control and Prevention; 2003.
26. Badri M, Ehrlich R, Wood R, Maartens G. Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations. AIDS 2001; 15:1143-1148.
27. Medecins Sans Frontieres. Untangling the Web of Price Reductions: a pricing guide for the purchase of ARVs for developing countries, 8th edn. Geneva: Medecins Sans Frontieres; 2005.
28. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: Treatment guidelines for a public health approach: 2003 revision. Geneva; WHO; 2004.
29. Médecins Sans Frontières. Affordable antiretrovirals in South Africa. Geneva: Medecins Sans Frontieres; 2001.
30. Downing R. Evaluating the Cavidi reverse transcriptase assay to monitor response to anti-retroviral therapy. XIV International AIDS Conference. Barcelona, July 2002 [abstract MoPeB3105].
31. CDC Office of Communications. Press release: new low-cost technologies offer practical solutions for developing world. Atlanta, GA: CDC Office of Communications; 2002.
32. Mandy W, Janossy G, Glencross DK, Barnett D, Mermin J, Downing R. Less expensive CD4+ T cell monitoring using panleucogating. XIV International AIDS Conference. Barcelona, July 2002 [abstract MoPeBS104].
33. Borgdorff MW, Floyd K, Broekmans JF. Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries. Bull WHO 2002; 80:217-227.
34. Morris CN, Burdge DR, Cheevers EJ. Economic impact of HIV infection in a cohort of male sugar mill workers in South Africa from the perspective of industry. Vancouver: Division of Infectious Diseases, University of British Columbia, Vancouver; 1999.
35. Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull WHO 1994; 72:429-445.
36. Gathe J Jr, Chu A, Yuen N, Petersen A. Durability of nelfinavir combination therapy after 4 years: 3-year extension data from Agouron Study 511. Abstracts of the Eighth European Conference on Clinical Aspects and Treatment of HIV-infection. Athens, Greece, October 2001 [poster LB10].
37. Staszewski S, Gallant J, Pozniak A, Suleiman J, DeJesus E, Koenig S, et al. Efficacy and safety of tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected patients naive to antiretroviral therapy (HAART): 48-week interim results. XIV International AIDS Conference. Barcelona, Spain, July 2002 [abstract LbOr17].
38. Medecins Sans Frontieres. Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries, 6th edn. Geneva: Medecins Sans Frontieres; 2004.
39. Alwano-Edyegu M, Marum E. Knowledge is power: voluntary HIV counselling and testing in Uganda. Geneva: UNAIDS; 1999.
40. Rosen S, Simon JL. Shifting the burden: the private sector's response to the AIDS epidemic in Africa. Bull WHO 2003; 81:131-137.